216529-53-2

Basic information

• Product Name: 2-PYRIDIN-4-YL-1-M-TOLYL-ETHANONE
• Synonyms: 2-PYRIDIN-4-YL-1-M-TOLYL-ETHANONE;Ethanone, 1-(3-Methylphenyl)-2-(4-pyridinyl)-;1-(3-Methylphenyl)-2-(4-pyridinyl)-ethanone
• CAS NO: 216529-53-2
• Molecular Formula: C₁₄H₁₃NO
• Molecular Weight: 211.26
• Mol File: 216529-53-2.mol
• Article Data: 10

Chemical Properties

• Melting Point: 115-116 °C(Solv: ethyl acetate (141-78-6); isopropyl ether (108-20-3))
• Boiling Point: 370.8 °C at 760 mmHg
• Flash Point: 185.6 °C
• Appearance: /
• Density: 1.105 g/cm³
• PKA: 5.22±0.10(Predicted)
• CAS DataBase Reference: 2-PYRIDIN-4-YL-1-M-TOLYL-ETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-PYRIDIN-4-YL-1-M-TOLYL-ETHANONE(216529-53-2)
• EPA Substance Registry System: 2-PYRIDIN-4-YL-1-M-TOLYL-ETHANONE(216529-53-2)

Safety Data

• Hazardous Substances Data: 216529-53-2(Hazardous Substances Data)

Usage

General Description

2-Pyridin-4-yl-1-m-tolyl-ethanone is a chemical compound that consists of a 2-pyridinyl group and a 1-m-tolyl group attached to an ethanone (or acetophenone) moiety. It is commonly used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. 2-PYRIDIN-4-YL-1-M-TOLYL-ETHANONE has potential applications in the field of medicine and agriculture due to its reactivity and ability to participate in various chemical reactions. It may also possess biological activities and may serve as a valuable starting material for the development of new drugs and pesticides. However, more research is needed to fully understand and utilize the potential uses of 2-Pyridin-4-yl-1-m-tolyl-ethanone.

Upstream product

• 6576-05-2 1-(4-fluorophenyl)-2-(4-pyridyl)ethanone 
• 108-89-4 picoline 
• 99-36-5 1-methoxycarbonyl-3-methylbenzene 
• 1711-06-4 3-Methylbenzoyl chloride 
• 26954-25-6 (4-pyridylmethyl)lithium 
• 135754-82-4 3-methyl-N-methoxy-N-methylbenzamide 
• 21384-43-0 1-(3-methylbenzoyl)-2-methylaziridine 

Downstream Products

• 216504-41-5 4-[5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]pyridine 
• 271577-17-4 1-(3-tolyl)-2-(1,3-dithietan-2-ylidene)-2-(pyridin-4-yl)ethanone 
• 325769-18-4 methyl 4-[4-(3-methylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]benzoate 
• 325769-12-8 N-methyl-[4-(3-methylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine 
• 224038-59-9 [4-(3-methylphenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine 
• 325769-02-6 methyl 4-[4-(3-methylphenyl)-5-(pyridin-4-yl)-1,3-thiazol-2-yl]phenyl sulfide 
• 365430-22-4 4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]pyridine 1-oxide 
• 325769-17-3 2-ethyl-4-(3-methylphenyl)-5-(4-pyridyl)-1,3-thiazole 

Relevant articles and documents

Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase

Starting from an initial HTS screening lead, a novel series of C(5)-substituted diaryl pyrazoles were developed that showed potent inhibition of p38α kinase. Key to this outcome was the switch from a pyridyl to pyrimidine at the C(4)-position leading to analogs that were potent in human whole blood based cell assay as well as in a number of animal efficacy models for rheumatoid arthritis. Ultimately, we identified a clinical candidate from this substrate; SD-0006.

THERAPEUTIC FLUOROETHYL UREAS

Compounds of the formula or a pharmaceutically acceptable salt thereof or a tautomer thereof, wherein A and B are as described herein, are useful for treating conditions afflicting mammals.

Synthesis and biological activities of 4-phenyl-5-pyridyl-1,3-thiazole derivatives as p38 MAP kinase inhibitors

A novel series of 4-phenyl-5-pyridyl-1,3-thiazole analogues possessing potent in vitro inhibitory activity against p38 mitogen-activated protein kinase and the release of tumor necrosis factor-α (TNF-α) from human monocytic THP-1 cells stimulated by lipopolysaccharide has been identified. Subsequent structure-activity relationship (SAR) studies and optimization for absorption, distribution, metabolism, and elimination (ADME) profiles led to the identification of compounds 7g and 10b as orally active lead candidates that block the in vivo production of proinflammatory cytokine (TNF-α). In pharmacokinetic studies, compound 10b showed good oral administration in mice and demonstrated significant in vivo anti-inflammatory activity in an anti-collagen monoclonal antibody-induced arthritis mouse model (minimum effective dose (MED)=30 mg/kg). Further elucidation of this class of compounds may provide novel anti-inflammatory agents, such as anti-rheumatoid arthritis drugs.